517 reports of this reaction
2.8% of all CLOBETASOL PROPIONATE OINTMENT USP, 0.05% reports
#5 most reported adverse reaction
PSORIASIS is the #5 most commonly reported adverse reaction for CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, manufactured by Encube Ethicals, Inc.. There are 517 FDA adverse event reports linking CLOBETASOL PROPIONATE OINTMENT USP, 0.05% to PSORIASIS. This represents approximately 2.8% of all 18,702 adverse event reports for this drug.
Patients taking CLOBETASOL PROPIONATE OINTMENT USP, 0.05% who experience psoriasis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIASIS is a less commonly reported adverse event for CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, but still significant enough to appear in the safety profile.
In addition to psoriasis, the following adverse reactions have been reported for CLOBETASOL PROPIONATE OINTMENT USP, 0.05%:
The following drugs have also been linked to psoriasis in FDA adverse event reports:
PSORIASIS has been reported as an adverse event in 517 FDA reports for CLOBETASOL PROPIONATE OINTMENT USP, 0.05%. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIASIS accounts for approximately 2.8% of all adverse event reports for CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, making it a notable side effect.
If you experience psoriasis while taking CLOBETASOL PROPIONATE OINTMENT USP, 0.05%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.